心脏移植:关注供体恢复策略、左心室辅助装置和新疗法。

Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies.

机构信息

Department of Cardiology, Complexo Hospitalario Universitario A Coruña (CHUAC), Instituto de Investigación Biomedica A Coruña (INIBIC), Centro de Investigacion Biomedica en Red Cardiovascular (CIBERCV), As Xubias 84, 15006 A Coruña, Spain.

Advocate Heart Institute, Naperville, IL, USA.

出版信息

Eur Heart J. 2022 Jun 14;43(23):2237-2246. doi: 10.1093/eurheartj/ehac204.

Abstract

Heart transplantation is advocated in selected patients with advanced heart failure in the absence of contraindications. Principal challenges in heart transplantation centre around an insufficient and underutilized donor organ pool, the need to individualize titration of immunosuppressive therapy, and to minimize late complications such as cardiac allograft vasculopathy, malignancy, and renal dysfunction. Advances have served to increase the organ donor pool by advocating the use of donors with underlying hepatitis C virus infection and by expanding the donor source to use hearts donated after circulatory death. New techniques to preserve the donor heart over prolonged ischaemic times, and enabling longer transport times in a safe manner, have been introduced. Mechanical circulatory support as a bridge to transplantation has allowed patients with advanced heart failure to avoid progressive deterioration in hepato-renal function while awaiting an optimal donor organ match. The management of the heart transplantation recipient remains a challenge despite advances in immunosuppression, which provide early gains in rejection avoidance but are associated with infections and late-outcome challenges. In this article, we review contemporary advances and challenges in this field to focus on donor recovery strategies, left ventricular assist devices, and immunosuppressive monitoring therapies with the potential to enhance outcomes. We also describe opportunities for future discovery to include a renewed focus on long-term survival, which continues to be an area that is under-studied and poorly characterized, non-human sources of organs for transplantation including xenotransplantation as well as chimeric transplantation, and technology competitive to human heart transplantation, such as tissue engineering.

摘要

心脏移植适用于无禁忌证的晚期心力衰竭患者。心脏移植中心面临的主要挑战包括供体器官不足且利用率低,需要个体化调整免疫抑制治疗,以及尽量减少晚期并发症,如心脏移植血管病、恶性肿瘤和肾功能障碍。通过提倡使用患有基础丙型肝炎病毒感染的供体,以及扩大供体来源以使用心脏停跳后捐献的心脏,新的技术增加了供体器官库。为了在长时间缺血期间保存供体心脏,并以安全的方式延长运输时间,已经引入了新的技术。机械循环支持作为移植的桥梁,使患有晚期心力衰竭的患者在等待最佳供体器官匹配时,避免肝肾功能进行性恶化。尽管免疫抑制方面取得了进展,但心脏移植受者的管理仍然是一个挑战,因为这些进展虽然早期避免了排斥反应,但也与感染和晚期预后挑战有关。在本文中,我们回顾了这一领域的当代进展和挑战,重点介绍了供体恢复策略、左心室辅助装置和免疫抑制监测治疗,这些治疗有可能改善预后。我们还描述了未来发现的机会,包括重新关注长期生存,这仍然是一个研究不足且特征描述不佳的领域,包括非人类来源的器官移植,如异种移植和嵌合移植,以及与人类心脏移植竞争的技术,如组织工程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索